Effects of Bardoxolone Methyl on Renal Perfusion
Research type
Research Study
Full title
Pilot Assessment of the Combined Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients with Chronic Kidney Disease and Type 2 Diabetes
IRAS ID
99705
Contact name
Chris McIntyre
Sponsor organisation
Reata Pharmaceutical Inc
Eudract number
2012-000806-20
Clinicaltrials.gov Identifier
Research summary
The purpose of this study is to more thoroughly understand the effects of bardoxolone methyl, an investigational drug being developed by Reata Pharmaceuticals, on the kidneys of those individuals afflicted with CKD and type 2 diabetes. This study is a single-center, open-label study. Both the participants and the doctor will know when and how much drug each participant received. The drug will be provided in capsules for everyone who participates in the study; the drug is to be taken in the morning one hour before or two hours after eating. No one in this study will receive a placebo (drugs without active ingredients). Bardoxolone methyl is an investigational (experiemental) drug that is being tested to treat CKD.
REC name
Yorkshire & The Humber - Sheffield Research Ethics Committee
REC reference
12/YH/0241
Date of REC Opinion
12 Jul 2012
REC opinion
Further Information Favourable Opinion